December 29, 2024
Introduction to Neutropenia and CDK 4/6 Inhibitors Neutropenia is a significant concern in cancer treatment, particularly when it comes to the use of CDK 4/6 inhibitors. […]
December 16, 2024
Explore our comprehensive educational series on bone marrow transplantation and pediatric acute lymphoblastic leukemia (ALL) management. This series delves into the intricacies of bone marrow transplantation, including the transplant process, conditioning regimens, and the critical role of immunosuppressants. Additionally, it covers the management of pediatric ALL, focusing on risk stratification, genetic risk groups, and innovative therapies such as immunotherapy and targeted treatments.
December 8, 2024
The FDA approval of IMFINZI for limited-stage small cell lung cancer is a momentous step forward, offering a much-needed new treatment option for patients facing this aggressive disease. As the first immunotherapy regimen approved in this setting, IMFINZI has the potential to redefine care and significantly improve outcomes. This milestone underscores the importance of continued research and innovation in the fight against lung cancer.
July 20, 2024
Discover innovative therapeutic strategies targeting quiescent cancer cells to combat tumor resistance and prevent relapse. Learn how to overcome treatment challenges.
February 7, 2024
The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
January 22, 2024
"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
January 19, 2024
Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
December 16, 2023
During her rotation in obstetrics and gynecology, a resident encountered a 28-year-old pregnant woman at 13 weeks gestational age, who already has three healthy children. I […]
May 17, 2021
What is Doxorubicin Transarterial Chemoembolization (TACE)?
Known as doxorubicin chemoembolization.
